ADMA BIOLOGICS INC (ADMA)
Health Care · Biotechnology · NASDAQ
ADMA Biologics is a vertically integrated biopharmaceutical company focused on plasma-derived specialty therapeutics for immune-compromised patient populations.
What ADMA BIOLOGICS INC does
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived therapeutics. The company specializes in treating immunodeficient patients and those at risk for infectious diseases through its vertically integrated model, which includes FDA-licensed plasma collection centers and a proprietary plasma fractionation and purification facility.
Themes: plasma-derived therapeutics, immunodeficiency treatments, biopharmaceutical manufacturing, vertical integration
Fundamentals
- Price$9.84 as of 2026-08-21 close
- Market cap$2.2B as of 2026-08-21
- 1-year return-42.5% 2025-08-21 close $17.10 → 2026-08-21 close $9.84
- P/E12.47 as of 2026-08-24
- Net margin+33.0% as of 2026-08-24
- Gross margin+64.7% as of 2026-08-24
- ROE+39.6% as of 2026-08-24
- Debt / equity0.48 as of 2026-08-24
- Revenue growth (YoY)+8.0% as of 2026-08-24
- Revenue CAGR (3y)+49.0% SEC XBRL
- Beta0.73 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How ADMA compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ADMA is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
54.4 #523 of 1,704 scored · #100 of 240 in Health Care
Setup 71st: no fresh 20-day breakout up or down; momentum 66th: MACD momentum is positive; weakest is volume and participation 30th: trading volume is about normal versus its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How ADMA BIOLOGICS INC looks technically
ADMA BIOLOGICS INC (ADMA) is trading 24.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 119 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 12 trading days ago. It is 51.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 24.5% below its 200-day average, the long-term trend line — a long-term downtrend | -24.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.94 | $8.94 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $13.04 | $13.04 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 9.2401. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 119 trading days ago — a "death cross", a bearish long-term signal | 119 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control | 26.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30) | 59.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($8.66 to $10.35) — its "stochastic" reading is 70 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 69.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $20.46 | $20.46 |
|---|---|---|
| From the 52-week high | it is 51.9% below its 52-week high (its highest price of the past year) | -51.9% |
| Above the 52-week low | it is 36.5% above its 52-week low (its lowest price of the past year) | +36.5% |
| Below the 52-week high | it is 51.9% below its highest point of the past year | 51.9% |
| Since a 20-day breakout | it made a new 20-day high about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day high about 12 trading days ago | 12 sessions |
| All-time high | its highest closing price on record is $25.67 (set on 2025-04-28) | $25.67 |
| Given back of the 52-week move | over the past year its closes ranged ($7.60 to $20.38), and it has recovered roughly a quarter of its fall from last year’s high — 18% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $15.50 to $15.91. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.5% |
| From the all-time high | it is 61.7% below its all-time high | -61.7% |
| Nearest price level | it is trading 5.6% above a support level at $9.29 — a price it turned at twice since 2026-07-10, most recently on 2026-08-13. Since 2024-08-21 it has 3 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.6% |
| All-time low | its lowest closing price on record is $1.01 (set on 2021-10-21) | $1.01 |
| Above the all-time low | it is 874.3% above its all-time low | +874.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 57th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3584 between its high and its low — about 3.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3584 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.27 and $10.41 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.27 – $9.34 – $10.41 |
| Typical daily range (% of price) | its price moves about 3.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.6% |
| Stretch from the 200-day average | it is trading 8.9 daily ranges below its 200-day average price (24.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.58× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 2.3% above the previous close 2 sessions ago and has not traded back through the level it left behind at 9.54 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.3% |
| Gap filled | a 5.8% gap up opened on 2026-08-06 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it took 5 sessions to close | 6 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 12.2 percentage points (the stock gained 14.6% while the market gained 2.3%) | +12.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 13.2 percentage points (the stock gained 16.3% while the market gained 3.1%) | +13.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 49.9 percentage points (the stock lost 38.9% while the market gained 11.1%) | -50.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 62.9 percentage points (the stock lost 42.5% while the market gained 20.5%) | -62.9% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.7% of the share price. | +6.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $10.91 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -9.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $9.73 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +1.1% |
Price levels it has turned at before
ADMA last closed at $9.84 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 14 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.29 | Support | 5.6% below the last close | turned there twice · 2026-07-10 to 2026-08-13 |
| $8.20 | Support | 16.7% below the last close | turned there twice · 2026-06-29 to 2026-07-24 |
| $7.47 | Support | 24.0% below the last close | turned there twice · 2026-05-07 to 2026-06-02 |
| $13.79 | Resistance | 40.1% above the last close | turned there twice · 2025-10-08 to 2025-11-07 |
| $14.59 | Resistance | 48.3% above the last close | turned there twice · 2025-08-07 to 2026-02-27 |
| $15.42 | Resistance | 56.7% above the last close | turned there six times · 2024-10-21 to 2026-02-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $9.24.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $11.43 and $12.78 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $9.24.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · lagging the market · Stretched far below its 200-day average (6+ daily ranges) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$17.00 range $12.00 – $21.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ADMA
- Consensus EPS estimate$0.1967 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the successful commercial performance of its flagship product, ASCENIV.","Operational risks associated with maintaining FDA compliance for plasma collection and manufacturing facilities.","Potential supply chain disruptions or volatility in the source plasma market."]
What changed in the latest 10-Q
AI-assisted comparison of ADMA's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-06) adds: 'We anticipate submitting a pre-Investigational New Drug ("IND") package to the FDA in fiscal year 2026, which could enable us to progress development of SG-001 directly into a registrational clinical trial' regarding SG-001 development timeline.
- Newer filing (2026-05-06) adds: 'Positive cash flows from operations continued throughout fiscal year 2025' regarding operational cash flow performance.
- Newer filing (2026-05-06) adds: 'Fiscal year 2026 will be our first full year of yield-enhanced production, supporting anticipated sustained margin expansion' regarding future production outlook.
- Removed:
- Older filing (2025-11-05) states: 'the full details of which can be found in the 2024 10-K' after discussing 2024 cash flow - removed in newer filing.
- Older filing (2025-11-05) states that Company 'believes it should experience meaningful revenue and earnings accretion beginning in the fourth quarter of 2025' - timing reference removed in newer filing.
- Older filing (2025-11-05) states: 'We expect these provisions to result in a reduction of current income tax liabilities and a corresponding reduction to income tax expense. While we are still evaluating these and other changes contained in the law, we do not expect these changes to have a material effect on our financial statements, including our effective tax rate' - replaced with different language in newer filing.
- Older filing (2025-11-05) refers to 'ten source plasma collection facilities' - changed in newer filing.
- Reworded:
- ASCENIV indication changed from 'adults and adolescents' (2025-11-05) to 'adults and children ages two and above' (2026-05-06).
- Reference to facility location changed from 'Boca Raton, FL' (2025-11-05) to 'Boca Raton, Florida' (2026-05-06).
- Term changed from 'immune globulin ("IG") products' (2025-11-05) to 'immune globulin products' (2026-05-06).
- Plasma collection facilities MFDS approval changed from 'three of our FDA-approved plasma collection centers also have approvals' (2025-11-05) to 'one of our FDA-approved plasma collection centers also has approval' (2026-05-06).
- Language regarding Hepatitis B program changed from 'as well as FDA approval' (2025-11-05) to 'and ADMA BioCenters has FDA approval' (2026-05-06).
- Tax provision language changed from 'We expect these provisions to result' (2025-11-05) to 'In 2025, these provisions resulted' (2026-05-06), indicating provisions have occurred rather than are expected.
- Annual report reference updated from '2024 10-K' filed 'March 18, 2025' (2025-11-05) to '2025 10-K' filed 'February 25, 2026' (2026-05-06).
- Yield enhancement accretion timing changed from 'beginning in the fourth quarter of 2025 and accelerating further into 2026' (2025-11-05) to 'accelerating further into 2026' (2026-05-06).
- Notes:
- The newer filing appears to be truncated at 'provide for certain redundancies for am' - the sentence is incomplete.
- The older filing also appears truncated at its end regarding real estate acquisition details.
Risk Factors
- Added:
- New bullet point added in 2026-05-06 filing: 'Issues in the development and use of AI may result in reputational harm and increased liability exposure.'
- Reworded:
- Changed from 'Although we achieved net income on a GAAP basis for the year ended December 31, 2024 for the first time' (2025-11-05) to 'Although we achieved net income on a GAAP basis for the fiscal years ended December 31, 2025 and 2024' (2026-05-06)
- Changed from 'continue to generate positive cashflows in the future' (2025-11-05) to 'continue to generate positive cash flows in the future' (2026-05-06) - spacing adjustment
- Changed from 'this Form 10-Q, the 2024 10-K' (2025-11-05) to 'this Quarterly Report on Form 10-Q, the 2025 10-K' (2026-05-06)
- Changed from 'our other filings with the U.S. Securities and Exchange Commission, or the SEC' (2025-11-05) to 'our other filings with the SEC' (2026-05-06)
- Notes:
- The older filing text appears truncated at the end ('Risks Relating to our Business' followed by partial text 'Although we achieved net income on a GAAP basis for the year ended December 3'), limiting ability to assess whether additional changes exist beyond the summary section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($50624) · 0 sells — 1 buying insider
- Last 180 days5 buys ($468294) · 3 sells ($476160) — 2 buying, 2 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-05-27. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ADMA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding ADMA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 59,235,902
- Reported value $533,715,473
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ADMA had 21,918,195 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ADMA had 9.79% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.83 days to cover at the same settlement.
- Reported short interest (shares) 21,918,195
- Short interest (% of shares outstanding) 9.79%
- Prior settlement (shares) 24,031,512
- Reported change -8.79%
- Days to cover (reported) 8.83
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- CSL Behring
- Grifols (GRFS)
- Takeda Pharmaceutical (TAK)
- Kedrion Biopharma
- Octapharma
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does ADMA BIOLOGICS INC (ADMA) do?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived therapeutics. The company specializes in treating immunodeficient patients and those at risk for infectious diseases through its vertically integrated model, which includes FDA-licensed plasma collection centers and a proprietary plasma fractionation and purification facility.
What sector is ADMA BIOLOGICS INC (ADMA) in?
ADMA BIOLOGICS INC (ADMA) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are ADMA BIOLOGICS INC's (ADMA) competitors?
Notable peers of ADMA BIOLOGICS INC (ADMA) include CSL Behring, Grifols, Takeda Pharmaceutical, Kedrion Biopharma and Octapharma. This peer set is informational only — not financial advice.
Is ADMA BIOLOGICS INC (ADMA) overbought or oversold right now?
ADMA BIOLOGICS INC (ADMA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 60, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ADMA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.